Reduced-Dose Chemotherapy for Lung Cancer
Trial Summary
What is the purpose of this trial?
This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, stable doses of anti-seizure medications are allowed if your CNS disease is treated and stable. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the drug combination used in the Reduced-Dose Chemotherapy for Lung Cancer trial?
Research shows that the combination of paclitaxel and carboplatin has been effective in treating non-small cell lung cancer, with response rates up to 48% and 1-year survival rates as high as 54%. Additionally, the combination of docetaxel and carboplatin has shown promising activity with a 48% response rate, indicating potential effectiveness for lung cancer treatment.12345
Is reduced-dose chemotherapy for lung cancer safe for humans?
Docetaxel, when combined with other drugs like cisplatin or carboplatin, is generally well-tolerated in treating lung cancer. The main side effect is neutropenia (a drop in white blood cells), but severe nerve damage and kidney problems are uncommon. Other combinations with docetaxel, such as with gemcitabine or irinotecan, also show manageable side effects, making these treatments generally safe for humans.56789
What makes the reduced-dose chemotherapy treatment for lung cancer unique?
The reduced-dose chemotherapy treatment for lung cancer is unique because it combines multiple drugs like Carboplatin, Docetaxel, and others, potentially reducing side effects while maintaining effectiveness. This approach may offer a better balance between treatment efficacy and tolerability compared to standard-dose regimens.7891011
Research Team
Julia Judd, DO
Principal Investigator
Fox Chase Cancer Center
Eligibility Criteria
This trial is for adults over 18 with stage IV lung cancer (small cell or non-small cell) or inoperable stage III. They may have had previous treatments and can have stable, treated brain metastases. Participants must be able to perform daily activities (ECOG 0-3), not be pregnant, agree to use contraception, and plan to receive one of the listed chemotherapy drugs.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive dose attenuated chemotherapy regimens based on their comorbidities and age
Follow-up
Participants are monitored for safety, efficacy, and progression-free survival
Open-label extension (optional)
Participants may continue to receive treatment and be monitored long-term
Treatment Details
Interventions
- Carboplatin
- Docetaxel
- Gemcitabine
- Irinotecan
- Lurbinectedin
- Nab paclitaxel
- Paclitaxel
- Pemetrexed
- Topotecan
Carboplatin is already approved in United States, European Union, Canada for the following indications:
- Ovarian cancer
- Testicular cancer
- Lung cancer
- Head and neck cancer
- Brain cancer
- Ovarian cancer
- Small cell lung cancer
- Ovarian cancer
- Small cell lung cancer
- Testicular cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fox Chase Cancer Center
Lead Sponsor